Lactobacillus: Friend or Foe for Systemic Lupus Erythematosus?
Lactobacillus: Friend or Foe for Systemic Lupus Erythematosus?
复制标题
DOI：
10.3389/fimmu.2022.883747
复制
发表时间：
2022
影响因子：
7.3
通讯作者：
中科院分区：
文献类型：
--
作者：
系统性红斑狼疮（SLE）的病因在很大程度上仍然未知，尽管人们已经很好地理解疾病发展需要基因和环境之间的复杂相互作用。微生物群作为激活剂，对免疫稳态至关重要。乳酸杆菌被认为是影响SLE发展的环境因子。然而，乳酸杆菌对SLE的有益治疗和抗炎作用也进行了探索。乳酸杆菌参与SLE的发现将揭示SLE的发展，以及发现微生物靶向生物标志物和新的治疗方法。本文就乳酸菌在SLE的发生、发展、治疗及预后中的作用进行综述。我们还讨论了不同菌株的乳酸杆菌对免疫细胞，小鼠狼疮和患者的影响。最后，我们试图阐明乳酸杆菌对SLE的潜在免疫学机制，并为进一步的微生物靶向治疗提供证据。
The cause of Systemic Lupus Erythematosus (SLE) remains largely unknown, despite the fact that it is well understood that a complex interaction between genes and environment is required for disease development. Microbiota serve as activators and are essential to immune homeostasis. Lactobacillus is thought to be an environmental agent affecting the development of SLE. However, beneficial therapeutic and anti-inflammatory effects of Lactobacillus on SLE were also explored. The discovery of Lactobacillus involvement in SLE will shed light on how SLE develops, as well as finding microbiota-targeted biomarkers and novel therapies. In this review, we attempt to describe the two sides of Lactobacillus in the occurrence, development, treatment and prognosis of SLE. We also discuss the effect of different strains Lactobacillus on immune cells, murine lupus, and patients. Finally, we try to illustrate the potential immunological mechanisms of Lactobacillus on SLE and provide evidence for further microbiota-targeted therapies.